Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors (JMT103)
A Phase I, Multi-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability and Preliminary Pharmacokinetics/Pharmacodynamics of JMT103 in Patients With Bone Metastases From Tumors
Sponsor: Covance
Listed as NCT03550508, this PHASE1 trial focuses on Bone Metastases and remains ongoing. Sponsored by Covance, it has been updated 5 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jul 2018 — Jun 2020 [monthly]
Recruiting PHASE1
First recorded
May 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Covance
- KingMed Diagnostics
- Quintiles, Inc.
- Shanghai JMT-Bio Inc.
For direct contact, visit the study record on ClinicalTrials.gov .